View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 09, 2019
Document and Entity Information
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Entity Registrant Name	FENNEC PHARMACEUTICALS INC.
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,895,830
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001211583
Amendment Flag	false
Trading Symbol	FENC

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 17,475	$ 22,781
Prepaid expenses	56	168
Other current assets	1	1
Total current assets	17,532	22,950
Non-current assets:
Deferred issuance costs	326
Amortization of deferred issuance costs	(29)
Total non-current assets:	297
Total assets	17,829	22,950
Current liabilities:
Accounts payable	1,228	1,032
Accrued liabilities	125	605
Total current liabilities	1,353	1,637
Commitments and Contingencies (Note 7)
Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 19,896 shares issued and outstanding (2018-19,896)	106,392	106,392
Additional paid-in capital	47,453	44,934
Accumulated deficit	(138,612)	(131,256)
Accumulated other comprehensive income	1,243	1,243
Total stockholders' equity	16,476	21,313
Total liabilities and stockholders' equity	$ 17,829	$ 22,950

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Jun. 30, 2019	Dec. 31, 2018
Condensed Consolidated Balance Sheets
Common stock, no par value	$ 0	$ 0
Common stock, shares issued	19,896	19,896
Common stock, shares outstanding	19,896	19,896

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Condensed Consolidated Statements of Operations
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	1,969	798	3,640	1,487
General and administrative	2,844	1,867	3,853	2,969
Loss from operations	(4,813)	(2,665)	(7,493)	(4,456)
Other (expense) income :
Unrealized gain (Note 4)	0	0	0	167
Other (loss)/gain	(10)	5	(10)	2
Interest expense	(17)		(29)
Interest income and other	110	73	176	132
Total other income/(expense), net	83	78	137	301
Net loss	$ (4,730)	$ (2,587)	$ (7,356)	$ (4,155)
Basic net loss per common share	$ (0.24)	$ (0.14)	$ (0.37)	$ (0.22)
Diluted net loss per common share	$ (0.24)	$ (0.14)	$ (0.37)	$ (0.22)
Weighted-average number of common shares outstanding, basic	19,896	18,585	19,896	18,508
Weighted-average number of common shares outstanding, diluted	19,896	18,585	19,896	18,508

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Operating activities:
Net loss	$ (4,730)	$ (2,587)	$ (7,356)	$ (4,155)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized gain on derivative	0	0	0	(167)
Amortization of deferred issuance cost	17	0	29	0
Stock-based compensation - contractors	331	83	374	197
Stock-based compensation - employees	1,669	1,207	1,890	1,381
Changes in operating assets and liabilities:
Prepaid assets	52	47	112	68
Other current assets	3	6	0	9
Accounts payable	(70)	(324)	196	(146)
Accrued liabilities	(28)	(2)	(480)	(484)
Net cash used in operating activities	(2,756)	(1,570)	(5,235)	(3,297)
Financing activities:
Short swing profit judgment offset with settlement expense	0	18	0	18
Capitalized deferred issuance cost	0	0	(71)	0
Options and warrants exercised	0	473	0	659
Net cash provided by financing activities	0	491	(71)	677
Decrease in cash and cash equivalents	(2,756)	(1,079)	(5,306)	(2,620)
Cash and cash equivalents - Beginning of period	20,231	26,719	22,781	28,260
Cash and cash equivalents - End of period	17,475	25,640	17,475	25,640
Non-cash deferred issuance cost (warrant value)	$ 0	$ 0	$ 255	$ 0

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 103,045	$ 43,837	$ 1,243	$ (121,368)	$ 26,757
Balance (in shares) at Dec. 31, 2017	18,411
Stock options issued \| Employees [Member]	$ 0	174	0	0	174
Stock options issued \| Contractors [Member]	0	114	0	0	114
Exercise of stock options	$ 71	(35)	0	0	36
Exercise of stock options (in shares)	23
Exercise of warrants	$ 221	(71)	0	0	150
Exercise of warrants (in shares)	50
Net loss	$ 0	0	0	(1,568)	(1,568)
Balance at Mar. 31, 2018	$ 103,337	44,019	1,243	(122,936)	25,663
Balance (in shares) at Mar. 31, 2018	18,484
Balance at Dec. 31, 2017	$ 103,045	43,837	1,243	(121,368)	26,757
Balance (in shares) at Dec. 31, 2017	18,411
Net loss					(4,155)
Balance at Jun. 30, 2018	$ 104,010	45,127	1,243	(125,523)	24,857
Balance (in shares) at Jun. 30, 2018	18,794
Balance at Mar. 31, 2018	$ 103,337	44,019	1,243	(122,936)	25,663
Balance (in shares) at Mar. 31, 2018	18,484
Short Swing Profit Manchester	$ 0	18	0	0	18
Stock options issued \| Employees [Member]	0	1,207	0	0	1,207
Stock options issued \| Contractors [Member]	0	83	0	0	83
Exercise of stock options	$ 75	(40)	0	0	35
Exercise of stock options (in shares)	18
Exercise of warrants	$ 598	(160)	0	0	438
Exercise of warrants (in shares)	292
Net loss	$ 0	0	0	(2,587)	(2,587)
Balance at Jun. 30, 2018	$ 104,010	45,127	1,243	(125,523)	24,857
Balance (in shares) at Jun. 30, 2018	18,794
Balance at Dec. 31, 2018	$ 106,392	44,934	1,243	(131,256)	21,313
Balance (in shares) at Dec. 31, 2018	19,896
Stock options issued \| Employees [Member]	$ 0	221	0	0	221
Stock options issued \| Contractors [Member]	0	43	0	0	43
Warrants issued to consultants	0	255	0	0	255
Net loss	0	0	0	(2,626)	(2,626)
Balance at Mar. 31, 2019	$ 106,392	45,453	1,243	(133,882)	19,206
Balance (in shares) at Mar. 31, 2019	19,896
Balance at Dec. 31, 2018	$ 106,392	44,934	1,243	(131,256)	21,313
Balance (in shares) at Dec. 31, 2018	19,896
Net loss					(7,356)
Balance at Jun. 30, 2019	$ 106,392	47,453	1,243	(138,612)	16,476
Balance (in shares) at Jun. 30, 2019	19,896
Balance at Mar. 31, 2019	$ 106,392	45,453	1,243	(133,882)	19,206
Balance (in shares) at Mar. 31, 2019	19,896
Stock options issued \| Employees [Member]	$ 0	1,669	0	0	1,669
Stock options issued \| Contractors [Member]	0	331	0	0	331
Net loss	0	0	0	(4,730)	(4,730)
Balance at Jun. 30, 2019	$ 106,392	$ 47,453	$ 1,243	$ (138,612)	$ 16,476
Balance (in shares) at Jun. 30, 2019	19,896

Nature of Business and Going Concern	6 Months Ended
Nature of Business and Going Concern	Jun. 30, 2019
Nature of Business and Going Concern
Nature of Business and Going Concern	1. Nature of Business and Going Concern Fennec Pharmaceuticals Inc. (“Fennec,” the “Company,” “we,” “us,” or “our”) is a biopharmaceutical company focused on the development of PEDMARKTM (a unique formulation of Sodium Thiosulfate (“STS”)) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. We incorporated under the Canada Business Corporations Act ("CBCA”) in September 1996. Effective on August 25, 2011, the Company continued from the CBCA to the Business Corporations Act (British Columbia) (the “Continuance”). The Continuance was approved by our shareholders at our June 2011 Annual and Special Meeting and by resolution of the Board of Directors on August 10, 2011. We have four wholly-owned subsidiaries: Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company and Fennec Pharmaceuticals (EU) Limited (“Fennec Limited”), an Ireland company formed in 2018. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive. These unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the three and six-months ended June 30, 2019, the Company incurred a loss from operations of $4,813 and $7,493, respectively. At June 30, 2019, it had an accumulated deficit of $138.6 million and had experienced negative cash flows from operating activities during the three and six-months ended June 30, 2019 of $2,756 and $5,235, respectively. On February 1, 2019, the Company's wholly-owned subsidiary, Fennec Pharmaceuticals Inc., entered into a Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank, an Arizona corporation, pursuant to which the Bank agreed to loan $12.5 million to the Company, to be made available upon New Drug Application NDA approval of PEDMARK by no later than September 30, 2020. The proceeds from the loan will be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Interest under the Term Loans shall bear interest, on the outstanding daily balance thereof, at a floating per annum rate equal to the Effective Interest Rate (as defined in the Loan and Security Agreement) which is equal to the sum of the Prime Rate published in the Wall Street Journal (currently 5.50%) plus one percent (1.00%). The debt facility is to have interest-only monthly payments due for the first eighteen months from the funding date and then monthly principal and interest payments are due through the remainder of the term which has a maturity date of October 1, 2023. In connection with the facility, Fennec granted Bridge Bank a warrant to purchase up to 39 common shares at an exercise price of $6.80 per common share, for a term of ten years from the date of issuance, subject to early termination under certain conditions. The Company believes the aforementioned debt facility, along with current cash on hand, provides sufficient funding for the Company to carry-out its planned activities including NDA approval and the commencement of commercialization efforts for the next twelve to fifteen months as it continues its strategic development of PEDMARKTM. These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

Significant Accounting Policies	6 Months Ended
Significant Accounting Policies	Jun. 30, 2019
Significant Accounting Policies
Significant Accounting Policies	2. Significant Accounting Policies Basis of presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with US GAAP and are the responsibility of the Company’s management. These unaudited interim condensed consolidated financial statements do not include all of the information and notes required by US GAAP for annual financial statements. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes filed with the Securities and Exchange Commission (“SEC”) in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2018. The Company’s accounting policies are materially consistent with those presented in the audited consolidated financial statements included in the Annual Report on Form 10‑K for the year ended December 31, 2018. These unaudited interim condensed consolidated financial statements have been prepared in U.S. dollars. All amounts presented are in thousands except for per share amounts. Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period. Actual results could differ from those estimates. In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company’s financial position at June 30, 2019 and to state fairly the results for the periods presented. The most significant estimates utilized during the six months ended June 30, 2019 included estimates necessary to value grants of stock options to contractors, employees and warrants issued to Bridge Bank to secure debt facility, disclosed in Note 5. New accounting pronouncements In August 2018, the FASB issued ASU 2018‑13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018‑13 removes certain disclosures, modifies certain disclosures and adds additional disclosures. The ASU is effective for us on January 1, 2020, and interim periods within that fiscal year. Early adoption is permitted. Certain disclosures in ASU 2018‑13 would need to be applied on a retrospective basis and others on a prospective basis. We are currently evaluating the impact this guidance may have on our consolidated financial statements. In June 2018, the FASB issued ASU 2018‑07 to expand the scope of ASC Topic 718, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. We adopted this policy as of January 1, 2019. The Company concluded after evaluation, that the impact of ASU 2018‑07 on our consolidated financial statements and disclosures was de minimis. In February 2016, the FASB issued ASU 2016‑02, Leases (Topic 842). The new guidance requires the recognition of lease liabilities, representing future minimum lease payments, on a discounted basis, and corresponding right-of-use assets on a balance sheet for most leases, along with requirements for enhanced disclosures to give financial statement users the ability to assess the amount, timing and uncertainty of cash flows arising from leasing arrangements. In July 2018, the FASB issued ASU 2018‑10 and 2018‑11 which permit application of the new guidance at the beginning of the year of adoption, recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, in addition to the method of applying the new guidance retrospectively to each prior reporting period presented. The ASU was effective for us on January 1, 2019. We have concluded the impact of this guidance is negligible on our consolidated financial statements, given we have no material leases. Cash and cash equivalents Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At June 30, 2019, the Company had $17,475 in cash, savings and money market accounts ($22,781 at December 31, 2018). At June 30, 2019, the Company held $135 in cash of which $74 (as presented in U.S. dollars) was in Canadian dollars ($121 at December 31, 2018 as presented in U.S. dollars). At June 30, 2019, the Company held $17,340 in money market investments. Money market investments typically have minimal risks. The Company has not experienced any loss or write-down of its money market investments since inception.

Earnings per Share

6 Months Ended

Jun. 30, 2019

Earnings per Share

Earnings Per Share

3. Earnings per Share

Earnings per common share is presented under two formats: basic earnings per common share and diluted earnings per common share. Basic earnings per common share is computed by dividing net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the period, plus the potentially dilutive impact of common stock equivalents (i.e. stock options and warrants). Dilutive common share equivalents consist of the incremental common shares issuable upon exercise of stock options and warrants. The following table sets forth the computation of basic and diluted net loss per share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Numerator:
Net (loss)	$	(4,730)	$	(2,587)	$	(7,356)	$	(4,155)

Denominator:
Weighted-average common shares, basic		19,896		18,585		19,896		18,508

Dilutive effect of stock options		—		—		—		—
Dilutive effect of warrants		—		—		—		—
Incremental dilutive shares		—		—		—		—

Weighted-average common shares, dilutive		19,896		18,585		19,896		18,508
Net (loss) per share, basic and diluted	$	(0.24)	$	(0.14)	$	(0.37)	$	(0.22)

The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:


	Three Months Ended June 30,		Six Months Ended June 30,
	2019	2018	2019	2018
Options to purchase common stock	2,843	2,579	2,843	2,579
Warrants to purchase common stock	39	1,020	39	1,020

Derivative Instruments

6 Months Ended

Jun. 30, 2019

Derivative Instruments

Derivative Instruments

4. Derivative Instruments

As of June 30, 2019 and 2018, the Company no longer has outstanding derivative instruments. Prior to March 31, 2018, the Company had outstanding options denominated in Canadian dollars which were not considered to be indexed to its own stock because the exercise price was denominated in Canadian dollars and the Company’s functional currency is U.S. dollars. Therefore, these options were treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company’s stock, because their exercise price is denominated in the same currency as the Company’s functional currency and are included in stockholders’ equity.

These options were recorded at their fair value as a liability at issuance and were re-measured at fair value as a liability at each subsequent balance sheet date until they were exercised, forfeited or expired. Any change in value between reporting periods was recorded as unrealized gain/(loss). The fair value of these options was estimated using the Black-Scholes option-pricing model.

Comparative data related to gain/(loss) recorded on re-measurement of the derivative liability for the three and six-month periods ended June 30, 2019 and 2018 are summarized in the table below. There is no cash flow impact for these derivatives until the options are exercised. When the options are exercised, the Company receives the proceeds from the exercise at the current exchange rate at the time of exercise.


	Three Months ended June 30,				Six Months Ended June 30,
Gain on Derivative Instruments	2019		2018		2019		2018
Options to contractors	$	—	$	—	$	—	$	167
Gain on Derivative Instruments	$	—	$	—	$	—	$	167

During the fiscal years ended December 31, 2011 and 2010, the Company issued 36 and 29, respectively, options to contractors with a Canadian dollar denominated strike price. Consequently, the Company had derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010‑13 "Compensation-Stock Compensation (Topic 718): Effect of denominating the exercise price of a share-based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors.

There are no Canadian dollar denominated contractor options remaining.

Stockholders' Equity

6 Months Ended

Jun. 30, 2019

Stockholders' Equity

Stockholders' Equity

5. Stockholders’ Equity

Authorized capital stock

The Company’s authorized capital stock consists of an unlimited number of shares of no-par common stock.

Warrants to Purchase Common Stock

On February 1, 2019, the Company issued warrants to purchase common stock priced in U.S. dollars with a weighted average price of $6.80 and had weighted average remaining life of 9.58 years as of June 30, 2019. During the three and six-months ended June 30, 2019, there were 0 warrants exercised resulting in gross proceeds to the Company of $0. The following table details the Company’s warrant activity from December 31, 2018:


	Common Shares Issuable Upon	Weighted-Average
Investor Warrants	Exercise of Outstanding Warrants	Exercise Price $USD
Outstanding December 31, 2018	—	—
Issued	39	6.80
Outstanding March 31, 2019	39	6.80
Issued	—	—
Outstanding June 30, 2019	39	6.80
Total	39	6.80

The value of warrants issued was estimated using the Black-Scholes option pricing model using the following assumptions in the table below. The expected volatility was determined using historical volatility of our stock based on the contractual life of the award. The Company capitalized the non-cash expense of $255 associated with issuing the above warrants on February 1, 2019. The Company also incurred legal, professional and share registration fees totaling $71 which were also capitalized. The combined capitalized asset, deferred issuance cost, has been placed on the balance sheet.


	Valuation Assumptions
Black-Scholes Model Assumptions	February 1, 2019
Expected dividend	0.00	%
Risk free rate	2.70	%
Expected volatility	179	%
Expected life	10	years

Stock option plan

On June 18, 2019, shareholders of the Company approved a resolution amending the maximum duration of options granted from eight (8) years to ten (10) years. At that same time, shareholders of the Company approved a resolution to extend the life of certain allocated options to the maximum term of ten (10) years. The weighted average life of affected options was increased by 2.98 years and the extension resulted in an increase in the fair value of all affected options by $1,438. The Company recognized $1,285 in expense immediately on all fully vested options. It will recognize an additional $153 in expense over the remaining vesting terms of the affected options.

The Compensation Committee of the Board of Directors administers the Company’s stock option plan. The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. Currently, the maximum number of option shares issuable is twenty-five percent (25%) of the total number of issued and outstanding shares of common stock. Based upon the current shares outstanding, a maximum of 5,000 options are authorized for issuance under the plan. For all options issued under the plan, the exercise price is the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of ten years from the date of grant. The stock option plan allows the issuance of Canadian and U.S. dollar grants. The table below outlines recognized contractor and employee expense for the three and six-month periods ended June 30, 2019 and 2018.


	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Contractor options expense recognized	$	331	$	83	$	374	$	197
Employee options expense recognized		1,669		1,207		1,890		1,381
Total option expense recognized	$	2,000	$	1,290	$	2,264	$	1,578

Stock option activity

The following is a summary of option activity for each of the quarterly periods in fiscal year 2019 for stock options denominated in U.S. dollars:


	Number of	Weighted-Average
US Denominated Options	Options (thousands)	Exercise Price $USD
Outstanding December 31, 2018	1,850	$	3.80
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2019	1,850	$	3.80
Granted	345		4.69
Outstanding at June 30, 2019	2,195	$	3.94

During the three-month period ended June 30, 2019, there were 345 US denominated options issued. Of the 2,195 US denominated options granted and outstanding at June 30, 2019, 1,762 are fully vested and exercisable.

The following is a summary of option activity for the three and six-month periods ended June 30, 2019 for stock options denominated in Canadian dollars:


	Number of	Weighted-Average
Canadian Denominated Options	Options (thousands)	Exercise Price $CAD
Outstanding December 31, 2018	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2019	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at June 30, 2019	648	$	2.43

For the three and six-month periods ended June 30, 2019, there was no issuance activity related to Canadian dollar denominated options. As of June 30, 2019, all 648 outstanding options denominated in Canadian dollars were fully vested and exercisable.

Valuation assumptions

The value of options granted were estimated using the Black-Scholes option pricing model using the following assumptions in the table below. The expected volatility was determined using historical volatility of our stock based on the contractual life of the award. There were 345 options issued during the three months ended June 30, 2019, (95 for the same period in 2018). Assumptions for the valuation of the option grants are described in the table below:


	Three Months Ended June 30,
Black-Scholes Model Assumptions	2019 (Employee grants)		2019 (Board of director grants)		2018
Expected dividend	0.00	%	0.00	%	0.00	%
Risk free rate	2.41	%	2.06	%	2.73-2.88	%
Expected volatility	136	%	156	%	139-144	%
Expected life	7	years	10	years	7	years

Fair Value Measurements

6 Months Ended

Jun. 30, 2019

Fair Value Measurements

Fair Value Measurements

6. Fair Value Measurements

The Company adopted the Fair Value Measurements and Disclosure Topic of the FASB in 2011. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.


	Fair Value Measurement at June 30, (in thousands)
	Quoted Price in Active
	Market for Identical				Significant Other		Significant
	Instruments				Observable Inputs		Unobservable Inputs
	Level 1				Level 2		Level 3		Total
	2019		2018		2019	2018	2019	2018	2019	2018
Assets
Cash and cash equivalents	135	(1)	6,032	(1)	17,340	19,608	—	—	17,475	25,640
Liabilities
Derivative liabilities	—		—		—	—	—	—	—	—

(1)

The Company held approximately, $135 in cash as of June 30, 2019, of which approximately, $74 was in Canadian funds (translated into U.S. dollars). As of June 30, 2018, the Company held approximately $6,032 of which approximately $80 was in Canadian funds (translated into U.S. dollars).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2019
Commitments and Contingencies
Commitments and Contingencies	7. Commitments and Contingencies Oregon Health & Science University Agreement On February 20, 2013, Fennec entered into a new exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including STS and their use in oncology (the "New OHSU Agreement"). OHSU will receive certain milestone payments, royalty on net sales for licensed products and a royalty on any consideration received from sublicensing of the licensed technology. The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec, unless earlier terminated as provided in the agreement. The New OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement. On May 18, 2015, Fennec negotiated an amendment ("Amendment 1") to the exclusive license agreement with OHSU. Amendment 1 expands the exclusive license agreement signed with OHSU on February 20, 2013 ("OHSU Agreement") to include the use of N-acetylcysteine as a standalone therapy and/or in combination with STS for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers. Further, Amendment 1 adjusts select milestone payments entered in the OHSU Agreement including but not limited to the royalty rate on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory approval of a licensed product. The term of Amendment 1 under the OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec or 8 years, whichever is later. In the event a licensed product obtains regulatory approval and is covered by the Orphan Drug Designation, the parties will in good faith amend the term of the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement. Executive Severance In the event of his termination with us other than for cause, we will be obligated to pay Mr. Raykov a one-time severance payment equal to twelve months of salary ($400,000). In the event of his termination with us other than for cause, we will be obligated to pay Mr. Andrade a one-time severance payment equal to six months of salary ($145,000). Leases We have an operating lease in Research Triangle Park, North Carolina utilizing small space within a commercial building. The operating lease has payments of $200 per month with no scheduled increases. This operating lease is terminable with 30 days’ notice and has no penalties or contingent payments due. Loan Security Agreement On February 1, 2019, the Company’s wholly owned subsidiary Fennec Pharmaceuticals Inc. entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Bridge Bank, a division of Western Alliance Bank, an Arizona corporation (the “Bank”), pursuant to which the Bank agreed to loan $12.5 million to Fennec Pharmaceuticals, Inc., to be made available upon New Drug Application (“NDA”) approval of PEDMARK by no later than September 30, 2020. The proceeds from the loan will be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Interest under the Term Loans shall bear interest, on the outstanding daily balance thereof, at a floating per annum rate equal to the Effective Interest Rate (as defined in the Loan and Security Agreement) which is equal to the sum of the Prime Rate published in the Wall Street Journal (currently 5.50%) plus one percent (1.00%). The debt facility is to have interest-only monthly payments due for the first eighteen months from the funding date and then monthly principal and interest payments are due through the remainder of the term which has a maturity date of October 1, 2023. In connection with the facility, Fennec granted Bridge Bank a warrant to purchase up to 39 common shares at an exercise price of $6.80 per common share, for a term of ten years from the date of issuance, subject to early termination under certain conditions. The combined value of the granted warrants and the associated costs to secure the loan facility (approximately $326 thousand) were capitalized on the balance sheet as a long-term asset. The asset, deferred issuance cost, will be amortized evenly over the full term of the agreement (56 months). During the quarter ended June 30, 2019, the Company recorded interest expense of roughly $17 ($29 since inception), as a result of the amortization of the asset related to deferred issuance cost.

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2019
Related Party Transactions
Related Party Transactions	8. Related Party Transactions In the second quarter of 2018, the Company recorded approximately $25 related to the net recovery of short-swing profits from one of the Company's shareholders under Section 16(b) of the Securities Exchange Act of 1934, as amended. The Company recognized these related party proceeds, net of $7 related legal fees and taxes, as an increase to additional paid-in capital in the accompanying interim unaudited condensed consolidated balance sheet as of June 30, 2018 as well as cash proceeds of approximately $18 as cash provided by financing activities in the accompanying interim unaudited condensed consolidated statement of cash flows for quarter ended June 30, 2018.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2019
Subsequent Events
Subsequent Events	9. Subsequent Events Management has evaluated subsequent events through the date of this filing and concluded there are no events of significance which require disclosure.

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2019
Significant Accounting Policies
Basis of presentation	Basis of presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with US GAAP and are the responsibility of the Company’s management. These unaudited interim condensed consolidated financial statements do not include all of the information and notes required by US GAAP for annual financial statements. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes filed with the Securities and Exchange Commission (“SEC”) in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2018. The Company’s accounting policies are materially consistent with those presented in the audited consolidated financial statements included in the Annual Report on Form 10‑K for the year ended December 31, 2018. These unaudited interim condensed consolidated financial statements have been prepared in U.S. dollars. All amounts presented are in thousands except for per share amounts.
Use of estimates	Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period. Actual results could differ from those estimates. In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company’s financial position at June 30, 2019 and to state fairly the results for the periods presented. The most significant estimates utilized during the six months ended June 30, 2019 included estimates necessary to value grants of stock options to contractors, employees and warrants issued to Bridge Bank to secure debt facility, disclosed in Note 5.
New accounting pronouncements	New accounting pronouncements In August 2018, the FASB issued ASU 2018‑13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018‑13 removes certain disclosures, modifies certain disclosures and adds additional disclosures. The ASU is effective for us on January 1, 2020, and interim periods within that fiscal year. Early adoption is permitted. Certain disclosures in ASU 2018‑13 would need to be applied on a retrospective basis and others on a prospective basis. We are currently evaluating the impact this guidance may have on our consolidated financial statements. In June 2018, the FASB issued ASU 2018‑07 to expand the scope of ASC Topic 718, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. We adopted this policy as of January 1, 2019. The Company concluded after evaluation, that the impact of ASU 2018‑07 on our consolidated financial statements and disclosures was de minimis. In February 2016, the FASB issued ASU 2016‑02, Leases (Topic 842). The new guidance requires the recognition of lease liabilities, representing future minimum lease payments, on a discounted basis, and corresponding right-of-use assets on a balance sheet for most leases, along with requirements for enhanced disclosures to give financial statement users the ability to assess the amount, timing and uncertainty of cash flows arising from leasing arrangements. In July 2018, the FASB issued ASU 2018‑10 and 2018‑11 which permit application of the new guidance at the beginning of the year of adoption, recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, in addition to the method of applying the new guidance retrospectively to each prior reporting period presented. The ASU was effective for us on January 1, 2019. We have concluded the impact of this guidance is negligible on our consolidated financial statements, given we have no material leases.
Cash and cash equivalents	Cash and cash equivalents Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At June 30, 2019, the Company had $17,475 in cash, savings and money market accounts ($22,781 at December 31, 2018). At June 30, 2019, the Company held $135 in cash of which $74 (as presented in U.S. dollars) was in Canadian dollars ($121 at December 31, 2018 as presented in U.S. dollars). At June 30, 2019, the Company held $17,340 in money market investments. Money market investments typically have minimal risks. The Company has not experienced any loss or write-down of its money market investments since inception.

Earnings per Share (Tables)

6 Months Ended

Jun. 30, 2019

Earnings per Share

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Numerator:
Net (loss)	$	(4,730)	$	(2,587)	$	(7,356)	$	(4,155)

Denominator:
Weighted-average common shares, basic		19,896		18,585		19,896		18,508

Dilutive effect of stock options		—		—		—		—
Dilutive effect of warrants		—		—		—		—
Incremental dilutive shares		—		—		—		—

Weighted-average common shares, dilutive		19,896		18,585		19,896		18,508
Net (loss) per share, basic and diluted	$	(0.24)	$	(0.14)	$	(0.37)	$	(0.22)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


	Three Months Ended June 30,		Six Months Ended June 30,
	2019	2018	2019	2018
Options to purchase common stock	2,843	2,579	2,843	2,579
Warrants to purchase common stock	39	1,020	39	1,020

Derivative Instruments (Tables)

6 Months Ended

Jun. 30, 2019

Derivative Instruments

Schedule of Unrealized Gain on Derivatives


	Three Months ended June 30,				Six Months Ended June 30,
Gain on Derivative Instruments	2019		2018		2019		2018
Options to contractors	$	—	$	—	$	—	$	167
Gain on Derivative Instruments	$	—	$	—	$	—	$	167

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2019

Stockholders' Equity

Schedule of Warrants Outstanding to Purchase Common Stock

The following table details the Company’s warrant activity from December 31, 2018:


	Common Shares Issuable Upon	Weighted-Average
Investor Warrants	Exercise of Outstanding Warrants	Exercise Price $USD
Outstanding December 31, 2018	—	—
Issued	39	6.80
Outstanding March 31, 2019	39	6.80
Issued	—	—
Outstanding June 30, 2019	39	6.80
Total	39	6.80


	Valuation Assumptions
Black-Scholes Model Assumptions	February 1, 2019
Expected dividend	0.00	%
Risk free rate	2.70	%
Expected volatility	179	%
Expected life	10	years

Schedule of Share Based Compensation, Stock Options Expense Recognized

The table below outlines recognized contractor and employee expense for the three and six-month periods ended June 30, 2019 and 2018.


	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Contractor options expense recognized	$	331	$	83	$	374	$	197
Employee options expense recognized		1,669		1,207		1,890		1,381
Total option expense recognized	$	2,000	$	1,290	$	2,264	$	1,578

Schedule of Share-based Compensation, Stock Options, Activity

The following is a summary of option activity for each of the quarterly periods in fiscal year 2019 for stock options denominated in U.S. dollars:


	Number of	Weighted-Average
US Denominated Options	Options (thousands)	Exercise Price $USD
Outstanding December 31, 2018	1,850	$	3.80
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2019	1,850	$	3.80
Granted	345		4.69
Outstanding at June 30, 2019	2,195	$	3.94

The following is a summary of option activity for the three and six-month periods ended June 30, 2019 for stock options denominated in Canadian dollars:


	Number of	Weighted-Average
Canadian Denominated Options	Options (thousands)	Exercise Price $CAD
Outstanding December 31, 2018	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2019	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at June 30, 2019	648	$	2.43

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

Assumptions for the valuation of the option grants are described in the table below:


	Three Months Ended June 30,
Black-Scholes Model Assumptions	2019 (Employee grants)		2019 (Board of director grants)		2018
Expected dividend	0.00	%	0.00	%	0.00	%
Risk free rate	2.41	%	2.06	%	2.73-2.88	%
Expected volatility	136	%	156	%	139-144	%
Expected life	7	years	10	years	7	years

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2019

Fair Value Measurements

Schedule of Assets/Liabilities Measured at Fair Value on Recurring Basis


	Fair Value Measurement at June 30, (in thousands)
	Quoted Price in Active
	Market for Identical				Significant Other		Significant
	Instruments				Observable Inputs		Unobservable Inputs
	Level 1				Level 2		Level 3		Total
	2019		2018		2019	2018	2019	2018	2019	2018
Assets
Cash and cash equivalents	135	(1)	6,032	(1)	17,340	19,608	—	—	17,475	25,640
Liabilities
Derivative liabilities	—		—		—	—	—	—	—	—

(1)

Nature of Business and Going Concern (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
	Feb. 01, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Going Concern [Line Items]
Net Cash Provided by (Used in) Operating Activities		$ (2,756)	$ (1,570)	$ (5,235)	$ (3,297)
Accumulated deficit		(138,612)		(138,612)		$ (131,256)
Operating Income (Loss)		$ (4,813)	$ (2,665)	$ (7,493)	$ (4,456)
Bridge Bank [Member] \| Loan And Security Agreement [Member]
Going Concern [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Bridge Bank [Member] \| Loan And Security Agreement [Member] \| Term Loan [Member]
Going Concern [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 12,500
Shares, Issued	39
Shares Issued, Price Per Share	$ 6.80
Debt Instrument, Basis Spread on Variable Rate	5.50%
Debt Instrument, Interest Rate, Stated Percentage	1.00%

Significant Accounting Policies (Details) $ in Thousands, $ in Thousands	Jun. 30, 2019 CAD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)	Jun. 30, 2018 CAD ($)	Jun. 30, 2018 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Money market investments		$ 17,475	$ 22,781
Cash	$ 74	135	$ 121	$ 80	$ 6,032
Money Market Funds [Member]
Summary Of Significant Accounting Policies [Line Items]
Money market investments		$ 17,340

Earnings per Share - Computation of Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Numerator:
Net (loss)	$ (4,730)	$ (2,626)	$ (2,587)	$ (1,568)	$ (7,356)	$ (4,155)
Denominator:
Weighted-average common shares, basic	19,896		18,585		19,896	18,508
Incremental dilutive shares	0		0		0	0
Weighted-average common shares, diluted	19,896		18,585		19,896	18,508
Net (loss) per share, basic and diluted	$ (0.24)		$ (0.14)		$ (0.37)	$ (0.22)
Warrant [Member]
Denominator:
Dilutive effect	0		0		0	0
Employee Stock Option [Member]
Denominator:
Dilutive effect	0		0		0	0

Earnings per Share - Outstanding Options and Warrants (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,843	2,579	2,843	2,579
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	39	1,020	39	1,020

Derivative Instruments - Gain on Derivative Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Gain/(Loss) on Derivative Instruments
Derivative Liability	$ 0	$ 0	$ 0	$ 0
Gain/(loss) on Derivative Instruments	0	0	0	167
Options [Member]
Gain/(Loss) on Derivative Instruments
Derivative Liability	$ 0	$ 167	$ 0	$ 167

Derivative Instruments - Additional Information (Details) - shares shares in Thousands	Dec. 31, 2011	Dec. 31, 2010
Canadian Dollar [Member]
Derivative [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	36	29

Stockholders' Equity - Warrants to Purchase Common Stock (Details) - $ / shares	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Stockholders' Equity
Common Shares Outstanding, beginning	39	0
Exercised	39
Issued	0	39
Common Shares Outstanding, end	39	39
Weighted-Average Outstanding, beginning	$ 6.80	$ 0.00
Exercised	6.80
Issued	0.00	6.80
Weighted-Average Outstanding, end	$ 6.80	$ 6.80

Stockholders' Equity - Recognized Contractor and Employee Expense (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Jun. 18, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Recognized Employee Expense [Line Items]
Stock or Unit Option Plan Expense	$ 1,285	$ 2,000	$ 1,290	$ 2,264	$ 1,578
Contractor Option [Member]
Recognized Employee Expense [Line Items]
Stock or Unit Option Plan Expense		331	83	374	197
Employee Stock Option [Member]
Recognized Employee Expense [Line Items]
Stock or Unit Option Plan Expense		$ 1,669	$ 1,207	$ 1,890	$ 1,381

Stockholders' Equity - Summary of Option Activity (Details) - $ / shares shares in Thousands	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Stock Option In Canadian Dollars [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at Beginning	648	648
Number of Options Granted	0	0
Number of Options Exercised	0	0
Number of Options Outstanding at Ending	648	648
Weighted-average Exercise Price outstanding at Beginning	$ 2.43	$ 2.43
Weighted-average Exercise Price Granted	0.00	0.00
Weighted-average Exercise Price Exercised	0.00	0.00
Weighted-average Exercise Price Outstanding at Ending	$ 2.43	$ 2.43
Stock Option In Us Dollars [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at Beginning	1,850	1,850
Number of Options Granted	345	0
Number of Options Exercised		0
Number of Options Outstanding at Ending	2,195	1,850
Weighted-average Exercise Price outstanding at Beginning	$ 3.80	$ 3.80
Weighted-average Exercise Price Granted	4.69	0
Weighted-average Exercise Price Exercised		0
Weighted-average Exercise Price Outstanding at Ending	$ 3.94	$ 3.80

Stockholders' Equity - Black-Scholes option (Details)		3 Months Ended
Stockholders' Equity - Black-Scholes option (Details)	Feb. 01, 2019	Jun. 30, 2019	Jun. 30, 2018
Expected dividend	0.00%		0.00%
Risk free rate	2.70%
Expected volatility	179.00%
Expected life	10 years		7 years
Director [Member]
Expected dividend		0.00%
Risk free rate		2.06%
Expected volatility		156.00%
Expected life		10 years
Employees [Member]
Expected dividend		0.00%
Risk free rate		2.41%
Expected volatility		136.00%
Expected life		7 years
Minimum [Member]
Risk free rate			2.73%
Expected volatility			139.00%
Maximum [Member]
Risk free rate			2.88%
Expected volatility			144.00%

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			3 Months Ended		6 Months Ended
	Jun. 18, 2019	Jun. 17, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Dec. 31, 2018
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 6.80		$ 6.80		$ 6.80	$ 0.00
Shares issuable under Stock Option Plan, as percent of shares outstanding					25.00%
Debt Issuance Cost, Gross, Noncurrent			$ 326		$ 326
Increased Class Or Warrant Or Right Outstanding Weighted Average Remaining Contractual Terms	2 years 11 months 23 days
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Increased	$ 1,438
Stock or Unit Option Plan Expense	1,285		$ 2,000	$ 1,290	$ 2,264	$ 1,578
Additional Stock Option Plan Expense	$ 153
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Number			345	95	345	95
US Denominated [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			2,195		2,195
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number			1,762		1,762
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Number			345		345
Stock Option In Canadian Dollars [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			648		648		648	648
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number			648		648
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Number			0		0
U.S.dollars [Member]
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 6.80		$ 6.80
Class Or Warrant Or Right Outstanding Weighted Average Remaining Contractual Terms					9 years 6 months 29 days
Proceeds from Warrant Exercises			$ 0		$ 0
Stock Issued During Period Shares Stock Warrants Exercised			0		0
Consultants [Member]
Stockholders Equity Note [Line Items]
Debt Issuance Cost, Gross, Noncurrent			$ 255		$ 255
Payment For Legal Professional and Registration Fees Incurred For Warrant Issue Capitalize					$ 71
Maximum [Member]
Stockholders Equity Note [Line Items]
Shares issuable under Stock Option Plan			5,000		5,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Minimum [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		8 years

Fair Value Measurements - Assets/Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	$ 17,475	$ 25,640
Derivative Liability	0	0
Quoted Price in Active Markets for Identical Instruments Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	135	6,032
Derivative Liability	0	0
Significant Other Observable Inputs Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	17,340	19,608
Derivative Liability	0	0
Significant Unobservable Inputs Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	0	0
Derivative Liability	$ 0	$ 0

Fair Value Measurements - Additional Information (Details) $ in Thousands, $ in Thousands	Jun. 30, 2019 CAD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)	Jun. 30, 2018 CAD ($)	Jun. 30, 2018 USD ($)
Fair Value Measurements
Cash	$ 74	$ 135	$ 121	$ 80	$ 6,032

Commitments and Contingencies (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended	6 Months Ended
	Feb. 01, 2019	Jun. 30, 2019	Jun. 30, 2019
Operating Leases, Rent Expense			$ 200
Finance Lease, Interest Expense		$ 17	$ 29
Duration Over Which The Costs Of Raising Finance Is To Be Amortised			56 months
Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 12,500
Debt Instrument, Basis Spread on Variable Rate	5.50%
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Shares Issued, Price Per Share	$ 6.80
Shares, Issued	39
Warrant [Member]
Debt Issuance Costs, Noncurrent, Net		326	$ 326
Rostislav Raykov [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause		400,000	400,000
Robert Andrade [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause		$ 145,000	$ 145,000

Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Related Party Transaction [Line Items]
Proceeds From Short Swing Profit Judgment Offset With Settlement Expense	$ 0	$ 18	$ 0	$ 18
Shareholder [Member]
Related Party Transaction [Line Items]
Proceeds From Short Swing Profit Judgment Offset With Settlement Expense		25
Related Party Transaction, Legal Fees And Taxes		7
Proceeds From Related Party		$ 18